In a target trial emulation using N3C data, adults prescribed metformin within six days of SARS-CoV-2 infection had about half the risk of long COVID or death within six months.
|Articles|May 18, 2021
FDA Grants EUA for COVID-19 Testing for Asymptomatic People
Author(s)John Parkinson
A Roche test can be used in individuals not showing signs of symptomatic disease.
Advertisement
Roche’s cobas SARS-CoV-2 Test was granted Food and Drug Administration (FDA) Emergency Use Authorization (EUA) and can be employed to test individuals without symptomatic disease.
The announcement was made yesterday and supports the guidance update from the US Centers for Disease Control and Prevention (CDC) to expand SARS-CoV-2 testing to include people without symptoms.
“One of the key strategies to reduce COVID-19 transmission is to stop the silent spread of disease early,” Cindy Perettie, head of Molecular Lab, Roche Diagnostics Solutions, said. “Expanding highly sensitive testing to include people who are at risk of exposure but do not show symptoms will help guide contact tracing, isolation and surveillance requirements, which are crucial for public health and the safe reopening of communities.”
The cobas SARS-CoV-2 Test for use on the cobas 6800/8800 Systems is a real-time RT-PCR test intended for the qualitative detection of nucleic acids from SARS-CoV-2 in healthcare provider-instructed self-collected anterior nasal (nasal) swab specimens (collected on site), and healthcare provider-collected nasal, nasopharyngeal, and oropharyngeal swab specimens collected from any individuals, including those suspected of COVID-19, and those without symptoms or other reasons to suspect COVID-19.
According to Roche, the cobas SARS-CoV-2 Test for asymptomatic people testing with is available in countries accepting the CE mark as well.
Advertisement
Related to this article
Approximately half of Long COVID patients were found to have meaningful symptom improvement within 3 years after acute infection and more than a quarter had completely remitted, in a large prospective cohort study.
The Pan American Health Organization has reportedly revoked the US measles elimination status after more than 12 months of continuous transmission, as 2026 cases top 5,400, states report 10 deaths, and kindergarten MMR coverage has fallen to 92.4%.
The Peggy Lillis Foundation's CEO and Co-founder Christian Lillis discusses the organization's initiatives for C diff month, and offers a glimpse of the upcoming Scientific Symposium they are hosting next week.
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
Here is some important information around this pathogen and the intestinal infection.
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Enteric fever (typhoid or paratyphoid fever) infection in travelers returning to the US is likely resistant to ciprofloxacin, and with some cases also resistant to ceftriaxone, CDC investigators advise treatment guided by susceptibility.
Advertisement
Advertisement